Geron Corporation Reports Third Quarter 2016 Financial Results and Recent Events
03 nov. 2016 16h05 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2016 and recent events. For...
Geron Provides Update on Imetelstat Trials Being Conducted by Janssen
12 sept. 2016 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of...
Geron Announces December Conference Presentation Webcasts
30 nov. 2015 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present...
Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis
16 sept. 2015 07h30 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced the dosing of the first patient in a Phase 2 clinical trial to evaluate imetelstat in...
Infinity Expands Clinical Development Program for IPI-926, an Oral Smoothened Antagonist Targeting the Hedgehog Pathway
22 juin 2011 08h00 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it is expanding its clinical development program for IPI-926, a novel, oral small...